This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing the potential of Roche's Susvimo, a surgical ocular implant designed to slowly release ranibizumab for the treatment of Wet-AMD.
Ticker(s): RHHBY, REGN, OCUL, EYPTWho's the expert?
Institution: UC Irvine
- Vitreoretinal Surgeon & Assistant Professor of Ophthalmology and Biomedical engineering at University of California Irvine.
- Treats over 300 patients with geographic atrophy.
- Developed a research program focused on multimodal imaging of ophthalmic structure and function, and directs the Eye Tech (ET) lab which focuses on two areas of translational vision science, advanced imaging techniques and cell replacement therapy.
- Conducted and presented the first functional metabolic imaging of stem cell-derived retinal organoids, revealing nuanced changes in metabolism that occur during retinal organoid development in vitro.
Interview GoalReviewing the current clinical landscape for wet-AMD and the potential of Roche's Susvimo slow release ocular implant after it was pulled from the market in 2022.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
